Foundayo (Orforglipron): What a Daily Tablet Changes
Quick answer
Foundayo is a once-daily orforglipron tablet licensed in the UK, offering an oral route without the fasting routine required for oral semaglutide. Taking a tablet rather than an injection does not remove the need for a doctor to assess suitability, monitor side effects and review ongoing treatment.
Foundayo contains orforglipron, a small-molecule GLP-1 receptor agonist taken as a tablet once daily. It matters because it is not a peptide, so it survives digestion without the strict water and fasting rules that earlier oral GLP-1 tablets required.
Practical differences from injections
- One tablet daily rather than a weekly injection, with or without food
- No needles, no sharps disposal and no refrigeration
- A shorter half-life, so a missed dose is felt sooner than with a weekly medicine
- Daily routine matters more; weekly injections tolerate a flexible schedule better
How it works
Orforglipron activates the same GLP-1 receptor as semaglutide, influencing appetite, fullness and glucose-dependent insulin release. Because it works on the same pathway, the side-effect profile is broadly familiar: nausea, vomiting, diarrhoea, constipation and reduced appetite, most often during dose increases.
Dose escalation
Treatment starts low and increases in steps, typically at four-week intervals, with each increase following clinical review. Escalating too quickly is the most common avoidable cause of intolerable nausea.
Where it sits clinically
Trial averages for weight reduction with orforglipron are meaningful but generally somewhat lower than those reported for tirzepatide. For a patient who will not use injections, an effective tablet they will actually take is the better treatment. For a patient seeking maximum average weight reduction, an injectable dual agonist may suit better. That trade-off is exactly what a specialist consultation is for.
What does not change
Eligibility criteria, contraindications, pregnancy precautions, nutritional priorities and the need for monitoring are the same as for injectable GLP-1 medicines. A tablet is a change of route, not a change of clinical seriousness — and it should not be bought without prescription or assessment.
Reviewed by
Dr Chinnadorai Rajeswaran
Specialist Endocrinologist · MBBS MRCP FRCP
Last Reviewed: November 2026
Read about complex severe obesity and related care.
Related insights
Weight Regain After GLP-1 Treatment: Why It Happens
Weight regain after stopping GLP-1 treatment is common because appetite and weight-regulating biology persist, though individual responses differ. Discuss a long-term plan with the prescriber before stopping or restarting, and do not alter doses independently.
Oral or Injectable GLP-1: How We Choose a Route
Oral and injectable GLP-1 medicines differ in absorption, dosing, evidence, and practical considerations; neither route is automatically best for everyone. A prescriber should choose based on the specific product, medical history, preferences, and local approval, with instructions followed exactly.
Retatrutide: What the Research Shows So Far
Retatrutide remains investigational, with ongoing trials assessing its benefits, risks and longer-term safety. The evidence is not yet complete, and it is not licensed or available at our clinics; products sold online are not approved alternatives.